News
Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...
37m
MarketBeat on MSNIs Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...
Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...
Gov. Glenn Youngkin saved about $7 million in state funds and $40 million in federal funds by vetoing a lower body-mass index ...
Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...
Another was a looming late-stage clinical trial of a closely watched pipeline drug that's loaded with potential. For a ...
As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...
Zepbound, Lilly’s obesity drug, has overtaken Novo’s equivalent, Wegovy, in the US and now commands over 50 per cent of the ...
12h
Lose It! on MSNShould I Take a Supplement If I Am on a GLP-1?If you experience symptoms like muscle cramping, irregular or fast heart rate, headaches, fatigue, nausea and vomiting, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results